Who are Dorzolamide-timolol-brimonidine and latanoprost's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dorzolamide-timolol-brimonidine-and-latanoprost.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Dorzolamide-timolol-brimonidine and latanoprost — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dorzolamide-timolol-brimonidine and latanoprost (Dorzolamide-timolol-brimonidine and latanoprost) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, alpha-2 agonist, and prostaglandin analog. Area

marketed Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, alpha-2 agonist, and prostaglandin analog Carbonic anhydrase II, beta-2 adrenergic receptor, alpha-2A adrenergic receptor, prostaglandin F receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Dorzolamide-timolol-brimonidine and latanoprost (Dorzolamide-timolol-brimonidine and latanoprost) — Laboratorios Sophia S.A de C.V.. This fixed-dose combination reduces intraocular pressure through four complementary mechanisms: carbonic anhydrase inhibition, beta-adrenergic blockade, alpha-2 adrenergic agonism, and prostaglandin F analog activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dorzolamide-timolol-brimonidine and latanoprost TARGET	Dorzolamide-timolol-brimonidine and latanoprost	Laboratorios Sophia S.A de C.V.	marketed	Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, alpha-2 agonist, and prostaglandin analog	Carbonic anhydrase II, beta-2 adrenergic receptor, alpha-2A adrenergic receptor, prostaglandin F receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, alpha-2 agonist, and prostaglandin analog class)

Laboratorios Sophia S.A de C.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dorzolamide-timolol-brimonidine and latanoprost — Competitive Intelligence Brief. https://druglandscape.com/ci/dorzolamide-timolol-brimonidine-and-latanoprost. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab